Masimo Receives FDA Clearance for Noninvasive Total Hemoglobin

AARC Corporate Partner, Masimo, announced it has received FDA clearance for its noninvasive and continuous total hemoglobin monitoring technology.

The Masimo SpHb technology requires no invasive procedures and provides continuous, real-time, pain-free results. This should allow clinicians to perform fewer lab tests, better manage blood transfusions and hemodialysis procedures which could help improve patient outcomes and reduce the cost-of-care.

Masimo joined the AARC Corporate Partner Program in 2003. The AARC’s Corporate Partner Program is comprised of best-in-class organizations interested in supporting the goals and work of the Association.